Please find enclosed herewith the proceedings of the Annual General Meeting of the Company held today i.e. September 29, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab Ltd held its 43rd Annual General Meeting on September 29, 2025, via video conferencing from 12:30 PM to 1:15 PM, attended by 33 members and 5 directors including Chairman & MD Mr. Mihir Shah. Four ordinary resolutions were considered: adoption of audited standalone and consolidated financial statements for FY 2024-25, re-appointment of Mr. Binoy B. Shah (DIN: 00440880) as a director retiring by rotation, approval of material related party transactions with Naxpar Pharma Private Limited, and re-appointment of the Secretarial Auditor. The Chairman noted the company's 43-year journey as a contract manufacturer for pharmaceutical formulations across liquid, ointment, powder, cosmetic, and herbal dosage forms with a significant global footprint. Statutory and Secretarial Auditors attended the meeting, with no qualifications or adverse remarks in the Statutory Auditor's report. E-voting was conducted from September 26-28, 2025, with results to be announced separately.
All four resolutions were passed with the requisite majority, indicating smooth shareholder approval on key matters including related party transactions. No red flags from auditors were reported. Voting results are still pending and may have a short-term bearing on stock sentiment once disclosed.